Trial Profile
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Irinotecan; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN; JAVELIN Gastric 300
- Sponsors EMD Serono; EMD Serono Research & Development Institute; Merck KGaA
- 15 Oct 2023 According to EMD Serono media release, the trial will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.
- 26 May 2022 According to Merck & Co media release, data from this trial will be presented at American Society of Clinical Oncology (ASCO) Annual Meeting.
- 11 Dec 2019 Status changed from active, no longer recruiting to completed.